文献速递慢性肾脏病血液净化与透析

滤过标志物作为ESRD与死亡预测因子:个体参与者数据Meta分析

Filtration Markers as Predictors of ESRD and Mortality: Individual Participant Data Meta-Analysis.
PubMed 文献 · Clin J Am Soc Nephrol · 2016-11-10

该个体患者水平Meta分析纳入三项一般人群/高危人群研究(n=17,903)和三项CKD研究(n=5415),比较BTP、B2M单独及平均eGFR与eGFRcr、eGFRcys及联合eGFRcr-cys对ESRD(2075例事件)和死亡(7275例事件)的关联、风险预测及再分类改善。结果显示新型标志物在调整既定危险因素后仅适度改善预测,加入白蛋白尿后改善减弱;作者认为这些标志物未提供实质性额外预后信息。

要点

  • BTP和B2M较eGFRcr改善风险关联并适度改善ESRD和死亡预测。
  • eGFRavg在两种结局和人群中提供最一致的关联与预测改善。
  • 加入白蛋白尿后,新型标志物对ESRD风险预测和分类的改善大幅减弱。

核心结论

  • 这些标志物未对eGFRcr和白蛋白尿提供实质性额外预后信息,但在eGFRcr不准确或无白蛋白尿时可能适用。
  • 作者认为,在临床实践中增加白蛋白尿测量以改善预后信息,可能比测量BTP和B2M更具成本效益。

研究设计与样本

  • 个体患者水平Meta分析,纳入三项一般人群/高危人群研究(n=17,903)和三项CKD研究(n=5415)。
  • 比较BTP估算的eGFR(eGFRBTP)、B2M估算的eGFR(eGFRB2M)单独及eGFRBTP、eGFRB2M、肌酐(eGFRcr)和胱抑素C(eGFRcys)的平均值(eGFRavg)与eGFRcr、eGFRcys及其联合(eGFRcr-cys)对ESRD(2075例事件)和死亡(7275例事件)的关联、风险预测及再分类改善。

主要发现

  • ESRD和死亡随访时间均值(标准差):一般人群/高危人群研究分别为13(4)年和6.2(3.2)年,CKD研究分别为14(5)年和7.5(3.9)年。
  • 与eGFRcr相比,eGFRBTP和eGFRB2M改善风险关联,并在调整既定危险因素后仍适度改善ESRD和死亡的预测。
  • eGFRavg在两种结局和人群中提供最一致的关联与预测改善;异质性评估未显示有临床意义的差异。
  • 对ESRD,加入白蛋白尿后,新型滤过标志物对风险预测和风险分类的改善大幅减弱。
  • 对死亡,加入白蛋白尿不影响新型标志物对风险预测的改善,但减弱风险分类的改善,尤其在CKD队列中。

临床怎么用

  • 这些标志物未对eGFRcr和白蛋白尿提供实质性额外预后信息,但在eGFRcr不准确或无白蛋白尿时可能适用。
  • 作者认为,在临床实践中增加白蛋白尿测量以改善预后信息,可能比测量BTP和B2M更具成本效益。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Serum β-trace protein (BTP) and β-2 microglobulin (B2M) are associated with risk of ESRD and death in the general population and in populations at high risk for these outcomes (GP/HR) and those with CKD, but results differ among studies. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We performed an individual patient-level meta-analysis including three GP/HR studies (n=17,903 participants) and three CKD studies (n=5415). We compared associations, risk prediction, and improvement in reclassification of eGFR using BTP (eGFRBTP) and B2M (eGFRB2M) alone and the average (eGFRavg) of eGFRBTP, eGFRB2M, creatinine (eGFRcr), and cystatin C (eGFRcys), to eGFRcr, eGFRcys, and their combination (eGFRcr-cys) for ESRD (2075 events) and death (7275 events). RESULTS: Mean (SD) follow up times for ESRD and mortality for GP/HR and CKD studies were 13 (4), 6.2 (3.2), 14 (5), and 7.5 (3.9) years, respectively. Compared with eGFRcr, eGFRBTP and eGFRB2M improved risk associations and modestly improved prediction for ESRD and death even after adjustment for established risk factors. eGFRavg provided the most consistent improvement in associations and prediction across both outcomes and populations. Assessment of heterogeneity did not yield clinically relevant differences. For ESRD, addition of albuminuria substantially attenuated the improvement in risk prediction and risk classification with novel filtration markers. For mortality, addition of albuminuria did not affect the improvement in risk prediction with the use of novel markers, but lessened improvement in risk classification, especially for the CKD cohort. CONCLUSIONS: These markers do not provide substantial additional prognostic information to eGFRcr and albuminuria, but may be appropriate in circumstances where eGFRcr is not accurate or albuminuria is not available. Educational efforts to increase measurement of albuminuria in clinical practice may be more cost-effective than measurement of BTP and B2M for improving prognostic information.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Inker LA, Coresh J, Sang Y, et al. Filtration Markers as Predictors of ESRD and Mortality: Individual Participant Data Meta-Analysis. Clin J Am Soc Nephrol. 2016. PMID: 28062677. doi:10.2215/CJN.03660316

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。